In addition, CD8+ T cells and CD4+ T cells are widely acknowledged as the main components of tumor-infiltrating lymphocytes (TLSs), and participate in anti-tumor immunity (Farhood et al., 2019; Miller et al., 2021). This evidence concerns the gene CD4 and neoplasm.